WATCH NOW: India's Revival Urgent Broadcast (available till 11:59pm tonight)
Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | -0.6 |
No. of shares | m | 188.52 |
% ch week | % | -0.1 |
% ch 1-mth | % | 6.0 |
% ch 12-mth | % | 42.9 |
52 week H/L | Rs | 1,150.0/600.0 |
No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
---|
ALEMBIC PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 495 | 792 | 709 | 645 | 664 | |
Low | Rs | 228 | 443 | 516 | 470 | 412 | |
Sales per share (Unadj.) | Rs | 109.1 | 167.0 | 166.3 | 166.1 | 208.7 | |
Earnings per share (Unadj.) | Rs | 15.0 | 38.2 | 21.4 | 21.9 | 31.0 | |
Diluted earnings per share | Rs | 15.0 | 38.2 | 21.4 | 21.9 | 31.0 | |
Cash flow per share (Unadj.) | Rs | 17.4 | 42.0 | 25.8 | 27.5 | 37.1 | |
Dividends per share (Unadj.) | Rs | 3.50 | 4.00 | 4.00 | 4.00 | 5.50 | |
Adj. dividends per share | Rs | 3.50 | 4.00 | 4.00 | 4.00 | 5.50 | |
Dividend yield (eoy) | % | 1.0 | 0.6 | 0.7 | 0.7 | 1.0 | |
Book value per share (Unadj.) | Rs | 46.9 | 84.9 | 100.9 | 117.8 | 144.2 | |
Adj. book value per share | Rs | 46.9 | 84.9 | 100.9 | 117.8 | 144.2 | |
Shares outstanding (eoy) | m | 188.52 | 188.52 | 188.52 | 188.52 | 188.52 | |
Bonus/Rights/Conversions | - | - | - | - | - | ||
Price / Sales ratio | x | 3.3 | 3.7 | 3.7 | 3.4 | 2.6 | |
Avg P/E ratio | x | 24.1 | 16.2 | 28.6 | 25.5 | 17.4 | |
P/CF ratio (eoy) | x | 20.8 | 14.7 | 23.8 | 20.3 | 14.5 | |
Price / Book Value ratio | x | 7.7 | 7.3 | 6.1 | 4.7 | 3.7 | |
Dividend payout | % | 23.3 | 10.5 | 18.7 | 18.3 | 17.7 | |
Avg Mkt Cap | Rs m | 68,122 | 116,383 | 115,459 | 105,090 | 101,461 | |
No. of employees | `000 | NA | NA | NA | NA | NA | |
Total wages/salary | Rs m | 3,068 | 4,214 | 5,588 | 6,228 | 7,467 | |
Avg. sales/employee | Rs Th | NM | NM | NM | NM | NM | |
Avg. wages/employee | Rs Th | NM | NM | NM | NM | NM | |
Avg. net profit/employee | Rs Th | NM | NM | NM | NM | NM |
ALEMBIC PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 20,561 | 31,487 | 31,346 | 31,308 | 39,347 | |
Other income | Rs m | 23 | 55 | 20 | 70 | 94 | |
Total revenues | Rs m | 20,584 | 31,542 | 31,366 | 31,378 | 39,441 | |
Gross profit | Rs m | 4,030 | 10,060 | 6,153 | 6,431 | 8,736 | |
Depreciation | Rs m | 444 | 722 | 830 | 1,055 | 1,152 | |
Interest | Rs m | 18 | 37 | 52 | 34 | 184 | |
Profit before tax | Rs m | 3,591 | 9,356 | 5,291 | 5,413 | 7,493 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 11 | |
Prior Period Items | Rs m | 2 | -2 | -38 | -81 | -93 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 764 | 2,160 | 1,222 | 1,204 | 1,568 | |
Profit after tax | Rs m | 2,829 | 7,194 | 4,031 | 4,128 | 5,844 | |
Gross profit margin | % | 19.6 | 31.9 | 19.6 | 20.5 | 22.2 | |
Effective tax rate | % | 21.3 | 23.1 | 23.1 | 22.2 | 20.9 | |
Net profit margin | % | 13.8 | 22.8 | 12.9 | 13.2 | 14.9 |
ALEMBIC PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 8,907 | 15,066 | 13,725 | 18,247 | 19,577 | |
Current liabilities | Rs m | 6,841 | 7,674 | 6,927 | 11,235 | 14,896 | |
Net working cap to sales | % | 10.1 | 23.5 | 21.7 | 22.4 | 11.9 | |
Current ratio | x | 1.3 | 2.0 | 2.0 | 1.6 | 1.3 | |
Inventory Days | Days | 68 | 67 | 74 | 86 | 90 | |
Debtors Days | Days | 64 | 41 | 39 | 61 | 45 | |
Net fixed assets | Rs m | 5,947 | 8,237 | 11,957 | 20,035 | 27,097 | |
Share capital | Rs m | 377 | 377 | 377 | 377 | 377 | |
"Free" reserves | Rs m | 8,374 | 15,416 | 18,646 | 21,824 | 26,811 | |
Net worth | Rs m | 8,846 | 16,005 | 19,023 | 22,201 | 27,188 | |
Long term debt | Rs m | 188 | 0 | 0 | 5,000 | 4,993 | |
Total assets | Rs m | 16,412 | 24,594 | 26,893 | 39,411 | 47,778 | |
Interest coverage | x | 202.7 | 255.2 | 102.2 | 160.2 | 41.7 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0.2 | 0.2 | |
Sales to assets ratio | x | 1.3 | 1.3 | 1.2 | 0.8 | 0.8 | |
Return on assets | % | 17.3 | 29.4 | 15.2 | 10.6 | 12.6 | |
Return on equity | % | 32.0 | 44.9 | 21.2 | 18.6 | 21.5 | |
Return on capital | % | 40.0 | 58.7 | 27.9 | 19.7 | 23.6 | |
Exports to sales | % | 39.3 | 55.7 | 49.8 | 46.4 | 0 | |
Imports to sales | % | 10.0 | 10.4 | 10.3 | 10.5 | 0 | |
Exports (fob) | Rs m | 8,085 | 17,551 | 15,626 | 14,535 | 0 | |
Imports (cif) | Rs m | 2,050 | 3,283 | 3,241 | 3,288 | 0 | |
Fx inflow | Rs m | 8,284 | 17,811 | 15,806 | 14,722 | 19,453 | |
Fx outflow | Rs m | 3,147 | 5,318 | 5,289 | 7,026 | 6,065 | |
Net fx | Rs m | 5,137 | 12,493 | 10,517 | 7,696 | 13,388 |
ALEMBIC PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1,718 | 9,304 | 3,286 | 3,124 | 8,120 | |
From Investments | Rs m | -2,556 | -3,105 | -4,859 | -8,844 | -7,556 | |
From Financial Activity | Rs m | 867 | -1,959 | -1,289 | 5,026 | 590 | |
Net Cashflow | Rs m | 29 | 4,240 | -2,862 | -693 | 1,153 |
Share Holding
|
Company Information
|
CHM: Chirayu R. Amin (MD) | COMP SEC: Rajkumar Baheti | YEAR OF INC: 2010 | BSE CODE: 533573 | FV (Rs): 2 | DIV YIELD (%): 0.6 |
Read: ALEMBIC PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: PIRAMAL ENTERPRISES NEULAND LABS GLENMARK PHARMA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare ALEMBIC PHARMA With: PIRAMAL ENTERPRISES NEULAND LABS GLENMARK PHARMA STRIDES PHARMA SCIENCE NATCO PHARMA
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.
More